Abstract
Acute graft-vs.-host disease (GVHD) remains one of the most significant barriers to successful allogeneic stem cell transplantation, accounting for a substantial portion of early transplant-related morbidity and mortality. Acute GVHD results from the complex interaction of donor T cells and host tissues that involves recognition of major and minor histocompatibility antigens in an inflammatory milieu. The current view of the pathogeneisis of acute GVHD is that it involves three steps: (1) tissue damage from conditioning regimen, (2) donor T-cell activation and (3) an inflammatory effector phase [1]. Recent studies demonstrating the importance of chemokines and regulatory T cells in acute GVHD have added further complexity to this model [2]. Within this context, clinical strategies that mitigate host tissue damage, down-regulate activated effector donor T cells, and reduce inflammatory cytokines in the early post transplant period should be effective in treating or preventing this condition. Indeed, strategies based, at least in part, on this model have continued to aid in the development of newer agents with promise in acute GVHD. However, until recently, it is only the cellular attack on host tissues that has been specifically targeted by GVHD prophylactic mechanisms, either with the use of a variety of pharmacologic agents or graft manipulation techniques, whereas therapeutics for the treatment of established acute GVHD have invoked the role of the cytokine cascades that may perpetuate ongoing GVHD reactions. In this article, we will review the current standards for prevention and treatment of acute GVHD, and discuss novel drugs and therapeutics that hold promise for improved prevention and management of established acute GVHD.
Keywords: Acute GVHD, Novel Drugs, allogeneic stem cell transplantation, minor histocompatibility antigens, inflammatory milieu, pathogeneisis, inflammatory cytokines
Current Pharmaceutical Design
Title: Novel Drugs for the Prevention and Treatment of Acute GVHD
Volume: 14 Issue: 20
Author(s): Corey Cutler and Joseph H. Antin
Affiliation:
Keywords: Acute GVHD, Novel Drugs, allogeneic stem cell transplantation, minor histocompatibility antigens, inflammatory milieu, pathogeneisis, inflammatory cytokines
Abstract: Acute graft-vs.-host disease (GVHD) remains one of the most significant barriers to successful allogeneic stem cell transplantation, accounting for a substantial portion of early transplant-related morbidity and mortality. Acute GVHD results from the complex interaction of donor T cells and host tissues that involves recognition of major and minor histocompatibility antigens in an inflammatory milieu. The current view of the pathogeneisis of acute GVHD is that it involves three steps: (1) tissue damage from conditioning regimen, (2) donor T-cell activation and (3) an inflammatory effector phase [1]. Recent studies demonstrating the importance of chemokines and regulatory T cells in acute GVHD have added further complexity to this model [2]. Within this context, clinical strategies that mitigate host tissue damage, down-regulate activated effector donor T cells, and reduce inflammatory cytokines in the early post transplant period should be effective in treating or preventing this condition. Indeed, strategies based, at least in part, on this model have continued to aid in the development of newer agents with promise in acute GVHD. However, until recently, it is only the cellular attack on host tissues that has been specifically targeted by GVHD prophylactic mechanisms, either with the use of a variety of pharmacologic agents or graft manipulation techniques, whereas therapeutics for the treatment of established acute GVHD have invoked the role of the cytokine cascades that may perpetuate ongoing GVHD reactions. In this article, we will review the current standards for prevention and treatment of acute GVHD, and discuss novel drugs and therapeutics that hold promise for improved prevention and management of established acute GVHD.
Export Options
About this article
Cite this article as:
Cutler Corey and Antin H. Joseph, Novel Drugs for the Prevention and Treatment of Acute GVHD, Current Pharmaceutical Design 2008; 14 (20) . https://dx.doi.org/10.2174/138161208785061436
DOI https://dx.doi.org/10.2174/138161208785061436 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Transition Metals for Conjugation of Polyunsaturated Acids and their Esters
Current Organic Chemistry Shigella Vaccine Development: Prospective Animal Models and Current Status
Current Pharmaceutical Biotechnology Synthesis, Characterization and Screening for Analgesic and Anti-inflammatory activities of 2, 5-disubstituted 1, 3, 4-oxadiazole derivatives
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Peptide Vaccines for Cancer Therapy
Recent Patents on Inflammation & Allergy Drug Discovery Evidence for Complex Binding Profiles and Species Differences at the Translocator Protein (TSPO) (18 kDa)
Current Molecular Medicine Concomitant Gene Mutations of MBL and CYBB in Chronic Granulomatous Disease: Implications for Host Defense
Inflammation & Allergy - Drug Targets (Discontinued) Overcoming Chondroitin Sulphate Proteoglycan Inhibition of Axon Growth in the Injured Brain: Lessons from Chondroitinase ABC
Current Pharmaceutical Design Osteoarthritis - An Update
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Placebos Used in Clinical Trials for Chinese Herbal Medicine
Recent Patents on Inflammation & Allergy Drug Discovery Effect of Environmental Substances on the Activity of Arylamine N-Acetyltransferases
Current Drug Metabolism Turning Up the Pressure on Vascular Disease
Current Neurovascular Research Meet Our Frontier Section Editor
Current Gene Therapy Preeclampsia as a Multifactorial Pregnancy Disorder: Clinical Symptoms,Diagnostic Tools and Research Strategies
Current Women`s Health Reviews Pharmacological Perspectives of Wasp Venom
Protein & Peptide Letters The Role of Fibrate Treatment in Dyslipidemia: An Overview
Current Pharmaceutical Design The Role of Immune and Inflammatory Mechanisms in ALS
Current Molecular Medicine Insights into the Role of Fc Gamma Receptors (FcγRs) Genetic Variations in Monoclonal Antibody-Based Anti-Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Editorial [ Inflammatory Bowel Disease and Inflammation-Associated Colon Cancer:Partners in Crime Guest Editor: Silvio Danese ]
Current Drug Targets Epithelial-Mesenchymal Transition: Implications in Cancer Progression and Metastasis
Current Pharmaceutical Biotechnology Biomarkers Associated with Stroke Risk in Atrial Fibrillation
Current Medicinal Chemistry